Early Deresuscitation Strategy Driven by Tissue Perfusion in Renal Replacement Therapy in Patients With Acute Renal Failure

NCT ID: NCT05817539

Last Updated: 2026-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-15

Study Completion Date

2028-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Intensive Care Unit (ICU) patients with acute kidney injury (AKI) and treated with renal replacement therapy (RRT) often present a fluid overload which is associated with morbidity (mechanical ventilation duration increase, kidney recovery decrease) and mortality.

Patients' prognostic could be improved by correcting the fluid overload with net ultrafiltration (UFnet) however it may lead to harmful iatrogenic hypovolemia responsible of deleterious ischemic lesions.

In usual practice, UF net prescription are variable and there are different international recommendations. Some observational studies suggest that using a UFnet between 1 et 1.75 mL/kg/h in fluid overloaded patient decrease mortality.

Fluid overload increases morbidity and mortality, particularly in RRT. Studies without RRT argue for an efficacy of management by decreasing the fluid overload .Cohort studies suggest to use a moderate UFnet instead of a low UFnet. Some data from studies on early versus late RRT that relate the fluid balance or correct the fluid overload during the early strategy argue for a beneficial effect of an early deresuscitation strategy

Consequently, the impact of a moderate UFnet (to decrease the fluid overload) compared to a low UFnet (to stabilize the fluid overload) in a randomized interventional study could be assessed.

The study hypothesis is that :

an early fluid overload deresuscitation protocol with a high UFnet (2 ml/kg/h) targeting both the negativation of cumulated fluid balance to reach a dry weight and the maintenance of tissue perfusion.

Compared to

fluid overload deresuscitation protocol with a low UFnet (between 0 and 1 ml/kg/h) to reach a stabilization of cumulated fluid balance without monitoring the tissue perfusion.

could improve overall, renal, hemodynamic and respiratory prognosis in fluid overloaded patients with renal replacement therapy in ICU

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury Fluid Overload

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants
For this protocol, the double blind is impossible to set up. Clinicians in charge of patients and implementing the depletion strategy cannot be blinded.

The patients will be blinded, they will not be aware of strategy applied. The medical staff will ensure that no information about the intervention is given to the patient.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Corrective strategy

In the experimental group, all patients will have a UFnet settled (2 ml/kg/h ) in order to reach the patient baseline body weight.

Group Type EXPERIMENTAL

Fluid balance negativation

Intervention Type PROCEDURE

During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .

When the patient's baseline body weight is reached the UF net will be settled to maintain it.

In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it

In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min and without tissue hypoperfusion.

Stabilizing strategy

In the control group, all patients will have a UFnet 2 ml settled (0 to 1 ml/kg/h) in order to stabilize the patient body weight.

Group Type OTHER

Body weight Stabilization

Intervention Type PROCEDURE

During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.

In case of weight stabilisation failure ( variation \>3% after 24h), the UF net can be increased to 1,5 ml/kg/h, as long as high intakes require UFnette at 1.5mL/kg/h to stabilize water balance, with daily reassessment.

In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluid balance negativation

During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .

When the patient's baseline body weight is reached the UF net will be settled to maintain it.

In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it

In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min and without tissue hypoperfusion.

Intervention Type PROCEDURE

Body weight Stabilization

During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.

In case of weight stabilisation failure ( variation \>3% after 24h), the UF net can be increased to 1,5 ml/kg/h, as long as high intakes require UFnette at 1.5mL/kg/h to stabilize water balance, with daily reassessment.

In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Acute kidney injury treated by continuous renal replacement therapy in ICU less than 7 days,
2. At least 1 organ failure during ICU in addition to AKI (mechanical ventilation or oxygen therapy or vascular filling \> 1000ml or vasopressor exposure \> 12 hours),
3. Weight loss of less than 3% since starting a net UF or Cumulative UF net less than 2000ml before inclusion,
4. Norepinephrine \< 0,5 µg/kg/min,
5. Absence of hypoperfusion signs defined by the presence of at least 2 out of 4 criteria:

* TRC \> 3s at the finger
* Marbrure score \> 2
* Lactate \> 2 mmol/L
* ScVO2\< 60%,
6. Fluid overload defined as follows :

* fluid overload \> 5% of base weight (based on cumulative fluid balance or a weight gain) and/or
* Obvious oedema of the lumbar region or flanks (oedema \> 1cm bucket depth).

Exclusion Criteria

1. Chronic renal failure hemodialyzed before admission to the ICU,
2. Mechanical circulatory support (ECMO, LVAD),
3. Pregnant, child -bearing age or lactating women,
4. Stroke based on the combination of central neurological symptoms (aphasia, hemiplegia, hemiparesis) associated with compatible brain imaging, less than 30 days,
5. Intestinal ischemia less than 7 days documented non-operated,
6. Interventional study participation or exclusion period on going,that may interfere with the present study
7. Guardianship, curatorship or safeguard of justice,
8. Absence of signature of free and informed consent by the patient and/or relative,
9. Patients not affiliated to a social security scheme or beneficiaries of a similar scheme
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier d'Ajaccio

Ajaccio, , France

Site Status NOT_YET_RECRUITING

CHU Amiens-Picardie

Amiens, , France

Site Status NOT_YET_RECRUITING

Service d'Anesthesie-Réanimation, Hôpital Louis Pradel, Hospices Civils de Lyon

Bron, , France

Site Status RECRUITING

CHU Caen Normandie

Caen, , France

Site Status NOT_YET_RECRUITING

Service de Réanimation, CHU de Dijon

Dijon, , France

Site Status RECRUITING

GHP Saint Joseph Marie Lannelongue

Le Plessis-Robinson, , France

Site Status NOT_YET_RECRUITING

CHU Lille - Hôpital Roger Salengro

Lille, , France

Site Status NOT_YET_RECRUITING

Hôpital Edouard Herriot, Groupement Hospitalier Centre

Lyon, , France

Site Status RECRUITING

Hôpital de la Croix Rousse

Lyon, , France

Site Status NOT_YET_RECRUITING

Hôpital de la Croix Rousse

Lyon, , France

Site Status RECRUITING

Service de Réanimation, Clinique de la Sauvegarde

Lyon, , France

Site Status RECRUITING

Hôpital Edouard Herriot

Lyon, , France

Site Status NOT_YET_RECRUITING

Département d'anesthésie réanimation Hôpital Européen Georges Pompidou

Paris, , France

Site Status RECRUITING

Hôpitaux de Bradois - CHRU Nancy

Vandœuvre-lès-Nancy, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Matthias JACQUET LAGREZE, MD PhD

Role: CONTACT

04 72 35 79 41 ext. +33

Julia CANTERINI, project manager

Role: CONTACT

04 27 85 66 28 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marie Geniez, Md

Role: primary

04 95 29 91 25 ext. +33

Osama ABOU ARAB, Pr

Role: primary

03 22 08 78 36 ext. +33

Matthias JACQUET LAGREZE, MD

Role: primary

04 72 35 79 41 ext. +33

Sébastien DERVILLE, Dr

Role: primary

02 31 06 47 36 ext. +33

Pierre-Grégoire GUINOT, MD

Role: primary

03 80 29 56 03 ext. +33

Thibaut GENTY, Dr

Role: primary

01 40 94 22 60 ext. +33

Laurent ROBRIQUET, Dr

Role: primary

03 20 44 40 84 ext. +33

Frank Bidar, MD

Role: primary

0472116942 ext. +33

Laurent Bitker, MD

Role: primary

04 26 10 92 69 ext. +33

Marie-Charlotte Delignette, MD

Role: primary

04 72 11 89 47 ext. 33

Guillaume Boulay, MD

Role: primary

04 78 64 06 50 ext. +33

Martin COUR, MD

Role: primary

04 72 11 28 62 ext. 33

Nicolas POLGE, MD

Role: primary

01 56 09 34 25 ext. +33

Philippe GUERCY, Professor

Role: primary

03 83 15 79 95 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

69HCL22_1095

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Outcome of ECMO and CRRT.
NCT05033509 COMPLETED